Supplementary Figure 6: TSLP from non-tumor derived sources is also critical for breast tumor metastasis in lungs | Nature Immunology

Supplementary Figure 6: TSLP from non-tumor derived sources is also critical for breast tumor metastasis in lungs

From: A tumor–myeloid cell axis, mediated via the cytokines IL-1α and TSLP, promotes the progression of breast cancer

Supplementary Figure 6: TSLP from non-tumor derived sources is also critical for breast tumor metastasis in lungs

a, Counts of tumor metastases in lungs at day 19 in wild-type (WT) or TSLP-KO mice injected with 4T1 cells i.v. n=3/group. b, Primary tumor volume in SPC-TSLP tumor-bearing mice post 0-28 day 4T1 injection. Right: tumor weights at day 28 (WT day 21, n=7; SPC-TSLP day 21, n=8; WT day 28, n=6, SPC-TSP day 28, n=7). c, Primary tumor volume in WT tumor-bearing mice treated with anti-TSLP antibodies in lungs post 0-28 day 4T1 injection. Right: tumor weights at day 28. n=6/group. d, A schematic summary of IL-1α and TSLP regulating breast tumor progression in vivo. Each symbol in (a-c) represents an individual mouse. Data are represented as mean ± s.e.m. Statistical analysis by unpaired, two-tailed t test with 95 % confidence intervals. Results in (b) are pooled data and (a, c) are representative of two independent experiments.

Back to article page